Inflammation and immune dysfunction in Parkinson disease
After age 3540, many individuals begin experiencing: Reduced muscle recovery Loss of lean muscle mass Increased soreness Slower healing Reduced exercise resilience Chronic inflammation and oxidative stress contribute significantly to muscle decline
Evolving procaspase-1-cleaving proteases with reduced off-target cleavage activity Although X(PC) demonstrated high selectivity for procaspase-1 over VAMP1, its transfection into mammalian cells lacking procaspase-1 (HEK293T cells) still resulted in reduced cell viability compared to a catalytically inactive X(PC) variant, consistent with residual off-target activity (Extended Data Fig
Nausea and vomiting were less common with longer-acting GLP-1 analogs than with short-acting GLP-1 analogs, probably because of the more gradual increase in plasma drug levels achieved with longer-acting GLP-1 analogs [17,59,67,74]
[in Italian] Altomare E, Colonna P, DAgostino C, et al